CBD should be driven by science, says OMG, as firm adopts new tech by Steve Jones October 1, 2026October 2, 2026 OMG Pharma is set to use technology developed by a Swiss biotech in a move to […]
Cannabis may ease anorexia symptoms, Australian study finds by Adam Sheldon September 8, 2026September 8, 2026
Avecho recruits biotech exec to drive CBD global licensing push by Adam Sheldon August 24, 2026August 27, 2026
‘Strong results’: Trial finds high-dose CBD reduced neuropathic pain by Adam Sheldon June 2, 2026June 8, 2026
News in brief: Cannaponics raise tops $2.5m; Avecho receives $1.98m R&D incentive; Elixinol backs capital raising plans by Adam Sheldon May 27, 2026June 8, 2026
The re-regulation of medicinal cannabis: is the TGA preparing to reassert control over THC? by Dr Teresa Nicoletti May 18, 2026May 19, 2026
News in brief: Judgment reserved in CDA Clinics QLD legal case; Nexalis completes Phase 1 IRX-616a dosing by Adam Sheldon May 18, 2026June 8, 2026
News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026June 11, 2026
Survey of 239 patients suggests CBG may benefit pain, sleep and anxiety by Adam Sheldon March 9, 2026March 10, 2026
Avecho prepares for potentially ‘transformative’ CBD trial results by Adam Sheldon March 4, 2026June 8, 2026
